EUCTR2010-020892-22-DEActive, not recruitingNot Applicable
A Long-term Extension Study to Assess the Safety and Efficacy of Fostamatinib Disodium (FosD) in the Treatment of Rheumatoid Arthritis - OSKIRA - X
Conditions
Trial Snapshot
- Phase
- Not Applicable
- Status
- Active, not recruiting
- Sponsor
- AstraZeneca AB
- Enrollment
- 2,000
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional clinical trial of medicinal product
Eligibility Criteria
- Sex
- All
Inclusion Criteria
- •For inclusion in the study patients must fulfil the following criteria. 1.Provision of informed consent, prior to any study-specific procedures. 2.Patients who have successfully completed a qualifying study (ie, Studies D4300C00001, D4300C00002, D4300C00003, D4300C00004 or D4300C00033) with fostamatinib disodium.
- •Patients who have participated in a qualifying study and who have been classified as non-responders due to pre-defined lack of efficacy at Week 12 (D4300C00001, D4300C00002, D4300C00003).
- •Patients who have participated in D4300C00033 and who require a dose reduction
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 1800
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 200
Exclusion Criteria
- •Patients must not enter the study if any of the following exclusion criteria are fulfilled:
- •1.Premature discontinuation of investigational product or withdrawal from the qualifying study.
- •2.Development of any of the withdrawal criteria from the qualifying study
- •3.Females who are pregnant or lactating.
- •4.Any other clinically significant disease or disorder, which in the opinion of the investigator (by its nature or by being inadequately controlled) might put the patient at risk due to participation in the study, or may influence the results of the study, or the patient’s ability to participate in the study.
Investigators
Similar Trials
Active, not recruiting
Phase 1
Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA) (OSKIRA-X)MedDRA version: 16.0Level: PTClassification code 10039073Term: Rheumatoid arthritisSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersRheumatoid ArthritisEUCTR2010-020892-22-BEAstraZeneca AB2,000
Active, not recruiting
Not Applicable
Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA) (OSKIRA-X)MedDRA version: 14.0Level: PTClassification code 10039073Term: Rheumatoid arthritisSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersRheumatoid ArthritisEUCTR2010-020892-22-LTAstraZeneca AB2,000
Active, not recruiting
Not Applicable
A Long-term Extension Study to Assess the Safety and Efficacy of Fostamatinib Disodium (FosD) in the Treatment of Rheumatoid Arthritis - OSKIRA-XPatients with active Rheumatoid Arthritis (RA) who have participated in a qualifying study.MedDRA version: 9.1Level: PTClassification code 10039073EUCTR2010-020892-22-ITASTRAZENECA2,000
Active, not recruiting
Not Applicable
A Long-term Extension Study to Assess the Safety and Efficacy of Fostamatinib Disodium (FosD) in the Treatment of Rheumatoid Arthritis - OSKIRA - XMedDRA version: 14.1Level: PTClassification code 10039073Term: Rheumatoid arthritisSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersRheumatoid ArthritisEUCTR2010-020892-22-PTAstraZeneca AB2,000
Active, not recruiting
Not Applicable
A Long-term Extension Study to Assess the Safety and Efficacy of Fostamatinib Disodium (FosD) in the Treatment of Rheumatoid Arthritis - OSKIRA - XMedDRA version: 12.1Level: LLTClassification code 10039073Term: Rheumatoid arthritisRheumatoid ArthritisEUCTR2010-020892-22-HUAstraZeneca AB2,000